Frank L Van De Veerdonk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2932058/publications.pdf

Version: 2024-02-01

269 papers 32,699 citations

82 h-index 169 g-index

292 all docs 292 docs citations

times ranked

292

44589 citing authors

#	Article	IF	CITATIONS
1	An Exaggerated Monocyte-Derived Cytokine Response to <i>Candida</i> Hyphae in Patients With Recurrent Vulvovaginal Candidiasis. Journal of Infectious Diseases, 2022, 225, 1796-1806.	4.0	11
2	Adult-onset autoinflammation caused by somatic mutations in UBA1: AÂDutch case series of patients with VEXAS. Journal of Allergy and Clinical Immunology, 2022, 149, 432-439.e4.	2.9	105
3	Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Regional Health - Europe, The, 2022, 13, 100266.	5 . 6	39
4	Managing secondary fungal infections in severe COVID-19: how to move forward?. Lancet Respiratory Medicine, the, 2022, 10, 127-128.	10.7	6
5	Anakinra restores cellular proteostasis by coupling mitochondrial redox balance to autophagy. Journal of Clinical Investigation, 2022, 132, .	8.2	7
6	Stimulating severe COVID-19: the potential role of GM-CSF antagonism. Lancet Respiratory Medicine, the, 2022, 10, 223-224.	10.7	10
7	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	30.7	206
8	Natural resistance against infections: focus on COVID-19. Trends in Immunology, 2022, 43, 106-116.	6.8	17
9	Borrelia burgdorferi Is a Poor Inducer of Gamma Interferon: Amplification Induced by Interleukin-12. Infection and Immunity, 2022, 90, iai0055821.	2.2	8
10	Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19. Frontiers in Immunology, 2022, 13, 838132.	4.8	10
11	Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	7.4	83
12	The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune Responses. Frontiers in Immunology, 2022, 13 , .	4.8	4
13	SARS-CoV-2 RNA in exhaled air of hospitalized COVID-19 patients. Scientific Reports, 2022, 12, .	3.3	3
14	Immunological Effects of Antiâ€'IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida Infections. Journal of Investigative Dermatology, 2022, 142, 2929-2939.e8.	0.7	5
15	Genetic determinants of fungi-induced ROS production are associated with the risk of invasive pulmonary aspergillosis. Redox Biology, 2022, 55, 102391.	9.0	1
16	The Challenge of Managing COVID-19 Associated Pulmonary Aspergillosis. Clinical Infectious Diseases, 2021, 73, e3615-e3616.	5.8	9
17	Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes. Journal of Infectious Diseases, 2021, 223, 214-224.	4.0	86
18	Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nature Immunology, 2021, 22, 2-6.	14.5	274

#	Article	lF	CITATIONS
19	Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects. European Journal of Immunology, 2021, 51, 662-671.	2.9	23
20	Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease. Cytokine, 2021, 137, 155334.	3.2	16
21	Mimicking Behçet's disease: GMâ€CSF gain of function mutation in a family suffering from a Behçet's diseaseâ€like disorder marked by extreme pathergy. Clinical and Experimental Immunology, 2021, 204, 189-198.	2.6	2
22	A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients. International Journal of Obesity, 2021, 45, 687-694.	3.4	35
23	Comparative host transcriptome in response to pathogenic fungi identifies common and species-specific transcriptional antifungal host response pathways. Computational and Structural Biotechnology Journal, 2021, 19, 647-663.	4.1	16
24	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Genome Medicine, 2021, 13, 7.	8.2	193
25	IL-38 prevents induction of trained immunity by inhibition of mTOR signaling. Journal of Leukocyte Biology, 2021, 110, 907-915.	3.3	20
26	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. Journal of Infectious Diseases, 2021, 223, 1322-1333.	4.0	61
27	A limited role of cytokine storm and fibrogenesis in COVID-19 related liver injury. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 166-168.	0.9	0
28	The Association of TSH and Thyroid Hormones With Lymphopenia in Bacterial Sepsis and COVID-19. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1994-2009.	3.6	15
29	Rare variants increase the risk of severe COVID-19. ELife, 2021, 10, .	6.0	5
30	A Human Dectin-2 Deficiency Associated With Invasive Aspergillosis. Journal of Infectious Diseases, 2021, 224, 1219-1224.	4.0	9
31	Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals. International Journal of Antimicrobial Agents, 2021, 57, 106293.	2.5	1
32	Data of common and species-specific transcriptional host responses to pathogenic fungi. Data in Brief, 2021, 35, 106928.	1.0	4
33	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	27.0	1,419
34	Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. Cell Reports Medicine, 2021, 2, 100289.	6. 5	15
35	Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. Genome Medicine, 2021, 13, 94.	8.2	5
36	Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis. MBio, 2021, 12, e0036921.	4.1	6

#	Article	IF	Citations
37	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Medicine, 2021, 47, 674-686.	8.2	49
38	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	8.2	106
39	The potential role for topical imiquimod in the treatment of chronic mucocutaneous candidiasis caused by gainâ€ofâ€function mutation in <scp>STAT1</scp> : A caseâ€report. Dermatologic Therapy, 2021, 34, e15043.	1.7	2
40	Anakinra Activates Superoxide Dismutase 2 to Mitigate Inflammasome Activity. International Journal of Molecular Sciences, 2021, 22, 6531.	4.1	15
41	SARS-CoV-2-Induced Multisystem Inflammatory Syndrome in a Young Adult: Case Report. SN Comprehensive Clinical Medicine, 2021, 3, 1773-1779.	0.6	6
42	Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. Bioscience Reports, 2021, 41, .	2.4	18
43	Comparison between myocardial function assessed by echocardiography during hospitalization for COVID-19 and at 4Âmonths follow-up. International Journal of Cardiovascular Imaging, 2021, 37, 3459-3467.	1.5	12
44	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 2021, 47, 867-886.	8.2	65
45	COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. Lancet Respiratory Medicine, the, 2021, 9, 795-802.	10.7	56
46	Challenges and Opportunities in Understanding Genetics of Fungal Diseases: Towards a Functional Genomics Approach. Infection and Immunity, 2021, 89, e0000521.	2.2	3
47	Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19. Frontiers in Immunology, 2021, 12, 719115.	4.8	76
48	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
49	Uncoupling of IL-6 signaling and LC3-associated phagocytosis drives immunoparalysis during sepsis. Cell Host and Microbe, 2021, 29, 1277-1293.e6.	11.0	26
50	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	7.4	498
51	Invasive pulmonary aspergillosis associated with viral pneumonitis. Current Opinion in Microbiology, 2021, 62, 21-27.	5.1	39
52	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	27.0	712
53	Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. Journal of Clinical Microbiology, 2021, 59, e0122921.	3.9	50
54	Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series. Med, 2021, 2, 1163-1170.e2.	4.4	31

#	Article	IF	Citations
55	Lysine methyltransferase G9a is an important modulator of trained immunity. Clinical and Translational Immunology, 2021, 10, e1253.	3.8	25
56	Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model. Virulence, 2021, 12, 2493-2508.	4.4	20
57	Effect of Convalescent Plasma on Organ Support–Free Days in Critically III Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	7.4	169
58	Multinational Observational Cohort Study of COVID-19–Associated Pulmonary Aspergillosis1. Emerging Infectious Diseases, 2021, 27, 2892-2898.	4.3	82
59	Implementation of Early Next-Generation Sequencing for Inborn Errors of Immunity: A Prospective Observational Cohort Study of Diagnostic Yield and Clinical Implications in Dutch Genome Diagnostic Centers. Frontiers in Immunology, 2021, 12, 780134.	4.8	12
60	STAT3 phosphorylation mediates the stimulatory effects of interferon alpha on B cell differentiation and activation in SLE. Rheumatology, 2020, 59, 668-677.	1.9	8
61	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. Clinical Infectious Diseases, 2020, 70, 349-350.	5.8	20
62	Platelets Modulate IFN-Î ³ Production against <i>Candida albicans</i> in Peripheral Blood Mononuclear Cells via Prostaglandins. Journal of Immunology, 2020, 204, 122-127.	0.8	17
63	Does Pulmonary Aspergillosis Complicate Coronavirus Disease 2019?. , 2020, 2, e0211.		10
64	Increased Plasma Heparanase Activity in COVID-19 Patients. Frontiers in Immunology, 2020, 11, 575047.	4.8	98
65	Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Reports Medicine, 2020, 1, 100073.	6.5	78
66	Blocking IL-1 to prevent respiratory failure in COVID-19. Critical Care, 2020, 24, 445.	5.8	76
67	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. Journal of Fungi (Basel, Switzerland), 2020, 6, 274.	3.5	7
68	Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin. Vaccines, 2020, 8, 713.	4.4	23
69	Presence of Genetic Variants Among Young Men With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 663.	7.4	626
70	Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. European Respiratory Journal, 2020, 56, 2002554.	6.7	98
71	A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases, The, 2020, 20, e192-e197.	9.1	1,165
72	Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19. JAMA Network Open, 2020, 3, e2017708.	5.9	57

#	Article	IF	CITATIONS
73	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1317.	7.4	671
74	Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nature Microbiology, 2020, 5, 1516-1531.	13.3	75
75	Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Critical Care, 2020, 24, 688.	5.8	100
76	Editorial overview: Emerging topics in host-fungus interactions. Current Opinion in Microbiology, 2020, 58, iii-v.	5.1	1
77	Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell, 2020, 181, 969-977.	28.9	358
78	Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe, The, 2020, 1, e53-e55.	7.3	158
79	Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity. Nature Communications, 2020, 11, 2282.	12.8	68
80	Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis. Cell Host and Microbe, 2020, 28, 117-123.e1.	11.0	210
81	COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients. Critical Care, 2020, 24, 263.	5.8	26
82	InvasiveAspergillusTracheobronchitis Emerging as a Highly Lethal Complication of Severe Influenza. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 646-648.	5.6	13
83	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	8.2	278
84	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Annals of the Rheumatic Diseases, 2020, 79, 536-544.	0.9	44
85	Primary immunodeficiencies in cytosolic patternâ€recognition receptor pathways: Toward hostâ€directed treatment strategies. Immunological Reviews, 2020, 297, 247-272.	6.0	10
86	Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19. Netherlands Heart Journal, 2020, 28, 410-417.	0.8	46
87	COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment. Journal of Fungi (Basel, Switzerland), 2020, 6, 91.	3.5	292
88	Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection. Seminars in Thrombosis and Hemostasis, 2020, 46, 835-837.	2.7	46
89	Subtle immunodeficiencies in nodular–bronchiectatic <i>Mycobacterium avium</i> complex lung disease. ERJ Open Research, 2020, 6, 00548-2020.	2.6	5
90	Immune defects in patients with pulmonary <i>Mycobacterium abscessus</i> disease without cystic fibrosis. ERJ Open Research, 2020, 6, 00590-2020.	2.6	5

#	Article	lF	CITATIONS
91	Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. ELife, 2020, 9 , .	6.0	235
92	<i>Aspergillus fumigatus</i> -specific antibodies in patients with chronic tuberculosis. International Journal of Tuberculosis and Lung Disease, 2020, 24, 853-856.	1.2	2
93	Late Breaking Abstract - Plasma cells and endothelitis in COVID-19 lung pathology. , 2020, , .		0
94	Diagnostic evaluation of bronchiectasis. Respiratory Medicine: X, 2019, 1, 100006.	1.4	2
95	STAT1 gain-of-function compromises skin host defense in the context of IFN- \hat{l}^3 signaling. Journal of Allergy and Clinical Immunology, 2019, 143, 1626-1629.e5.	2.9	6
96	Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies. Genome Medicine, 2019, 11, 38.	8.2	49
97	A systems genomics approach identifies <i>SIGLEC15</i> as a susceptibility factor in recurrent vulvovaginal candidiasis. Science Translational Medicine, 2019, 11, .	12.4	38
98	Tetraspanin CD82 Organizes Dectin-1 into Signaling Domains to Mediate Cellular Responses to <i>Candida albicans</i>). Journal of Immunology, 2019, 202, 3256-3266.	0.8	27
99	Detection of Invasive Aspergillosis in Critically Ill Patients with Influenza: The Role of Plasma Galactomannan. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 636-638.	5.6	14
100	A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans. Journal of Infectious Diseases, 2019, 220, 862-872.	4.0	17
101	The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the ClinicalÂDiagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1763-1770.	3.8	381
102	Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection. Journal of Fungi (Basel, Switzerland), 2019, 5, 116.	3 . 5	12
103	Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. Journal of Critical Care, 2019, 50, 59-65.	2.2	94
104	Clinical and immunological characteristics of patients with pulmonary Mycobacterium abscessus disease without cystic fibrosis. , 2019, , .		0
105	Recognition of DHN-melanin by a C-type lectin receptor is required for immunity to Aspergillus. Nature, 2018, 555, 382-386.	27.8	157
106	Microbiological and immunological characteristics of a lethal pulmonary Aspergillus niger infection in a non-neutropenic patient. Medical Mycology Case Reports, 2018, 21, 4-7.	1.3	4
107	Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell, 2018, 172, 135-146.e9.	28.9	485
108	Are histones real pathogenic agents in sepsis?. Nature Reviews Immunology, 2018, 18, 148-148.	22.7	1

#	Article	IF	CITATIONS
109	Biology of <scp>IL</scp> â€38 and its role in disease. Immunological Reviews, 2018, 281, 191-196.	6.0	81
110	Differential Kinetics of Aspergillus nidulans and Aspergillus fumigatus Phagocytosis. Journal of Innate Immunity, 2018, 10, 145-160.	3.8	16
111	Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clinical Microbiology and Infection, 2018, 24, 1264-1272.	6.0	107
112	The effects of signal transducer and activator of transcription three mutations on human platelets. Platelets, 2018, 29, 602-609.	2.3	2
113	Understanding the role of host immune responses in invasive candidiasis. Intensive Care Medicine, 2018, 44, 1310-1314.	8.2	12
114	967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis. Open Forum Infectious Diseases, 2018, 5, S36-S36.	0.9	11
115	Moderate correlation between systemic ILâ€6 responses and CRP with trough concentrations of voriconazole. British Journal of Clinical Pharmacology, 2018, 84, 1980-1988.	2.4	36
116	Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. Journal of Allergy and Clinical Immunology, 2018, 142, 1932-1946.	2.9	344
117	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respiratory Medicine, the, 2018, 6, 782-792.	10.7	638
118	Host Genetic Signatures of Susceptibility to Fungal Disease. Current Topics in Microbiology and Immunology, 2018, 422, 237-263.	1.1	20
119	HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis. Clinical and Experimental Immunology, 2018, 194, 205-219.	2.6	11
120	Genetic deficiency of NOD2 confers resistance to invasive aspergillosis. Nature Communications, 2018, 9, 2636.	12.8	38
121	Antifungal immune responses: emerging host–pathogen interactions and translational implications. Genome Medicine, 2018, 10, 39.	8.2	11
122	The immunopathology of sepsis and potential therapeutic targets. Nature Reviews Immunology, 2017, 17, 407-420.	22.7	1,183
123	Adjuvant interferon-gamma immunotherapy in a patient with progressive cerebral Nocardia abscesses. International Journal of Infectious Diseases, 2017, 59, 25-28.	3.3	7
124	Personalized medicine in influenza. Current Opinion in Pulmonary Medicine, 2017, 23, 237-240.	2.6	3
125	Uric acid priming in human monocytes is driven by the AKT–PRAS40 autophagy pathway. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 5485-5490.	7.1	114
126	Influenza-associated Aspergillosis in Critically III Patients. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 524-527.	5.6	176

#	Article	IF	CITATIONS
127	<i>MST1R</i> mutation as a genetic cause of Lady Windermere syndrome. European Respiratory Journal, 2017, 49, 1601478.	6.7	18
128	Itraconazole or Amphotericin B for Talaromycosis. New England Journal of Medicine, 2017, 377, 1402-1403.	27.0	4
129	Toll-like receptorÂ2 induced cytotoxic T-lymphocyte-associated proteinÂ4 regulates Aspergillus-induced regulatory T-cells with pro-inflammatory characteristics. Scientific Reports, 2017, 7, 11500.	3.3	14
130	Aspergillus fumigatus morphology and dynamic host interactions. Nature Reviews Microbiology, 2017, 15, 661-674.	28.6	402
131	A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831.	14.5	506
132	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
133	Immunotherapeutic approaches to treatment of fungal diseases. Lancet Infectious Diseases, The, 2017, 17, e393-e402.	9.1	98
134	New and recurrent <i><scp>STAT</scp>1</i> mutations in seven Chinese patients with chronic mucocutaneous candidiasis. International Journal of Dermatology, 2017, 56, e30-e33.	1.0	9
135	Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease. Open Forum Infectious Diseases, 2017, 4, ofx202.	0.9	56
136	The Multifaceted Role of T-Helper Responses in Host Defense against Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2017, 3, 55.	3.5	44
137	Autoimmune Regulator Deficiency Results in a Decrease in STAT1 Levels in Human Monocytes. Frontiers in Immunology, 2017, 8, 820.	4.8	24
138	Development of Endotoxin Tolerance Does Not Influence the Response to a Challenge with the Mucosal Live-Attenuated Influenza Vaccine in Humans In Vivo. Frontiers in Immunology, 2017, 8, 1600.	4.8	12
139	The Absence of NOD1 Enhances Killing of Aspergillus fumigatus Through Modulation of Dectin-1 Expression. Frontiers in Immunology, 2017, 8, 1777.	4.8	17
140	Rewiring monocyte glucose metabolism via C-type lectin signaling protects against disseminated candidiasis. PLoS Pathogens, 2017, 13, e1006632.	4.7	73
141	An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility. PLoS ONE, 2017, 12, e0180824.	2.5	24
142	An Omics Perspective on Candida Infections: Toward Next-Generation Diagnosis and Therapy. Frontiers in Microbiology, 2016, 7, 154.	3.5	9
143	When the Fight against Fungi Goes Wrong. PLoS Pathogens, 2016, 12, e1005400.	4.7	12
144	Reducing hypoxia and inflammation during invasive pulmonary aspergillosis by targeting the Interleukin-1 receptor. Scientific Reports, 2016, 6, 26490.	3.3	33

#	Article	IF	Citations
145	The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis. Journal of Interferon and Cytokine Research, 2016, 36, 267-276.	1.2	45
146	Immunologic defects in severe mucocutaneous HSV-2 infections: Response to IFN- \hat{I}^3 therapy. Journal of Allergy and Clinical Immunology, 2016, 138, 895-898.	2.9	6
147	Treatment options for chronic mucocutaneous candidiasis. Journal of Infection, 2016, 72, S56-S60.	3.3	27
148	Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood, 2016, 127, 3154-3164.	1.4	465
149	Understanding human immune function using the resources from the Human Functional Genomics Project. Nature Medicine, 2016, 22, 831-833.	30.7	63
150	CBLB ubiquitin ligase: a major regulator of antifungal immunity. Nature Medicine, 2016, 22, 834-835.	30.7	3
151	Th2 and Th9 responses in patients with chronic mucocutaneous candidiasis and hyper″gE syndrome. Clinical and Experimental Allergy, 2016, 46, 1564-1574.	2.9	26
152	Progressive multifocal leukoencephalopathy in an immunocompetent patient. Annals of Clinical and Translational Neurology, 2016, 3, 226-232.	3.7	19
153	LC3-associated phagocytosis: a crucial mechanism for antifungal host defence against <i>Aspergillus fumigatus</i> . Cellular Microbiology, 2016, 18, 1208-1216.	2.1	42
154	Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. Cell Metabolism, 2016, 24, 807-819.	16.2	584
155	In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infectious Diseases, The, 2016, 16, e251-e260.	9.1	123
156	Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory. American Journal of Hematology, 2016, 91, E482-E490.	4.1	28
157	IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nature Communications, 2016, 7, 10791.	12.8	201
158	A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans. Cell, 2016, 167, 1099-1110.e14.	28.9	275
159	<i>Aspergillus</i> Cell Wall Chitin Induces Anti- and Proinflammatory Cytokines in Human PBMCs via the Fc-Î ³ Receptor/Syk/PI3K Pathway. MBio, 2016, 7, .	4.1	58
160	The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. Journal of Allergy and Clinical Immunology, 2016, 137, 223-230.	2.9	247
161	Basic Genetics and Immunology of Candida Infections. Infectious Disease Clinics of North America, 2016, 30, 85-102.	5.1	26
162	Deficient interleukin-17 production in response to <i>Mycobacterium abscessus</i> ii>in cystic fibrosis. European Respiratory Journal, 2016, 47, 990-993.	6.7	17

#	Article	IF	Citations
163	Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nature Immunology, 2016, 17, 406-413.	14.5	437
164	Human Neutrophils Use Different Mechanisms To Kill <i>Aspergillus fumigatus</i> Conidia and Hyphae: Evidence from Phagocyte Defects. Journal of Immunology, 2016, 196, 1272-1283.	0.8	162
165	Aspergillus Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity. Cell Host and Microbe, 2016, 19, 79-90.	11.0	183
166	Modulation of inflammation by autophagy: Consequences for human disease. Autophagy, 2016, 12, 245-260.	9.1	287
167	Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of $L-1\hat{l}^2$ and by the induction of endogenous $L-1$ Ra. Annals of the Rheumatic Diseases, 2016, 75, 1219-1227.	0.9	63
168	IL-1 \hat{I}^2 /IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections. PLoS Pathogens, 2016, 12, e1005973.	4.7	237
169	Defective trained immunity in patients with STAT-1-dependent chronic mucocutaneaous candidiasis. Clinical and Experimental Immunology, 2015, 181, 434-440.	2.6	35
170	Gainâ€ofâ€function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). European Journal of Immunology, 2015, 45, 2834-2846.	2.9	111
171	Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses. Thrombosis and Haemostasis, 2015, 113, 1035-1045.	3.4	40
172	A missense mutation underlies defective <scp>SOCS</scp> 4 function in a family with autoimmunity. Journal of Internal Medicine, 2015, 278, 203-210.	6.0	6
173	The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 963-974.	2.9	69
174	Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients. Clinical and Experimental Allergy, 2015, 45, 423-437.	2.9	67
175	Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis. Immunology Letters, 2015, 167, 54-56.	2.5	19
176	Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37. Frontiers in Microbiology, 2015, 5, 762.	3.5	21
177	TREML4 adds fuel to the TLR7 fire. Nature Immunology, 2015, 16, 445-446.	14.5	3
178	Th17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis. BMC Infectious Diseases, 2015, 15, 140.	2.9	23
179	The interplay between inflammasome activation and antifungal host defense. Immunological Reviews, 2015, 265, 172-180.	6.0	53
180	Immune defence against Candida fungal infections. Nature Reviews Immunology, 2015, 15, 630-642.	22.7	440

#	Article	IF	CITATIONS
181	Pathogenic NLRP3 Inflammasome Activity during Candida Infection Is Negatively Regulated by IL-22 via Activation of NLRC4 and IL-1Ra. Cell Host and Microbe, 2015, 18, 198-209.	11.0	74
182	Borrelia- induced cytokine production is mediated by spleen tyrosine kinase (Syk) but is Dectin-1 and Dectin-2 independent. Cytokine, 2015, 76, 465-472.	3.2	14
183	Antifungal innate immunity: recognition and inflammatory networks. Seminars in Immunopathology, 2015, 37, 107-116.	6.1	79
184	Inflammasome-Independent Regulation of IL-1-Family Cytokines. Annual Review of Immunology, 2015, 33, 49-77.	21.8	275
185	An anti-inflammatory property of Candida albicans \hat{l}^2 -glucan: Induction of high levels of interleukin-1 receptor antagonist via a Dectin-1/CR3 independent mechanism. Cytokine, 2015, 71, 215-222.	3.2	42
186	IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. Journal of Infectious Diseases, 2015, 211, 1646-1657.	4.0	54
187	Compartmentalized Cytokine Responses in Hidradenitis Suppurativa. PLoS ONE, 2015, 10, e0130522.	2.5	57
188	The Role of Interleukin-1 Family Members in the Host Defence Against Aspergillus fumigatus. Mycopathologia, 2014, 178, 395-401.	3.1	19
189	The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunology, 2014, 15, 55.	2.2	54
190	IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3526-3531.	7.1	273
191	IL-37 Inhibits Inflammasome Activation and Disease Severity in Murine Aspergillosis. PLoS Pathogens, 2014, 10, e1004462.	4.7	136
192	Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer. PLoS Pathogens, 2014, 10, e1004485.	4.7	167
193	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nature Communications, 2014, 5, 4675.	12.8	76
194	A Polysaccharide Virulence Factor from Aspergillus fumigatus Elicits Anti-inflammatory Effects through Induction of Interleukin-1 Receptor Antagonist. PLoS Pathogens, 2014, 10, e1003936.	4.7	117
195	Deficient autophagy unravels the ROS paradox in chronic granulomatous disease. Autophagy, 2014, 10, 1141-1142.	9.1	47
196	Immunotherapy. Current Opinion in Infectious Diseases, 2014, 27, 511-516.	3.1	23
197	Cytokine Production Assays Reveal Discriminatory Immune Defects in Adults with Recurrent Infections and Noninfectious Inflammation. Vaccine Journal, 2014, 21, 1061-1069.	3.1	5
198	Skin Microbiome Imbalance in Patients with STAT1/STAT3 Defects Impairs Innate Host Defense Responses. Journal of Innate Immunity, 2014, 6, 253-262.	3.8	83

#	Article	IF	CITATIONS
199	Autophagy is redundant for the host defense against systemic Candida albicans infections. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 711-722.	2.9	35
200	The potential impact of the pulmonary microbiome on immunopathogenesis of <i>Aspergillus</i> å€related lung disease. European Journal of Immunology, 2014, 44, 3156-3165.	2.9	55
201	Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infectious Diseases, 2014, 14, 166.	2.9	195
202	mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity. Science, 2014, 345, 1250684.	12.6	1,517
203	Two independent killing mechanisms of Candida albicans by human neutrophils: evidence from innate immunity defects. Blood, 2014, 124, 590-597.	1.4	152
204	Circulating galectin-3 in infections and non-infectious inflammatory diseases. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1605-1610.	2.9	38
205	Genetic susceptibility to <i>Candida</i> infections. EMBO Molecular Medicine, 2013, 5, 805-813.	6.9	100
206	Biology of IL-36 cytokines and their role in disease. Seminars in Immunology, 2013, 25, 458-465.	5.6	144
207	The effects of in vivo B-cell depleting therapy on ex-vivo cytokine production. Transplant Immunology, 2013, 28, 183-188.	1.2	4
208	The <scp>IL</scp> â€36 receptor pathway regulates <i><scp>A</scp>spergillus fumigatusâ€</i> induced <scp>T</scp> h1 and <scp>T</scp> h17 responses. European Journal of Immunology, 2013, 43, 416-426.	2.9	93
209	Corticosteroids Block Autophagy Protein Recruitment in <i>Aspergillus fumigatus</i> Phagosomes via Targeting Dectin-1/Syk Kinase Signaling. Journal of Immunology, 2013, 191, 1287-1299.	0.8	124
210	<i>Aspergillus fumigatus</i> àꀓInduced IL-22 Is Not Restricted to a Specific Th Cell Subset and Is Dependent on Complement Receptor 3. Journal of Immunology, 2013, 190, 5629-5639.	0.8	38
211	New Insights in the Immunobiology of IL-1 Family Members. Frontiers in Immunology, 2013, 4, 167.	4.8	137
212	Autophagy Modulates Borrelia burgdorferi-induced Production of Interleukin- $1\hat{l}^2$ (IL- $1\hat{l}^2$). Journal of Biological Chemistry, 2013, 288, 8658-8666.	3.4	21
213	Deficient Candida-Specific T-Helper 17 Response During Sepsis. Journal of Infectious Diseases, 2012, 206, 1798-1802.	4.0	15
214	IL-18 Serum Concentration Is Markedly Elevated in Acute EBV Infection and Can Serve as a Marker for Disease Severity. Journal of Infectious Diseases, 2012, 206, 197-201.	4.0	51
215	Neutrophil-Mediated Inhibition of Proinflammatory Cytokine Responses. Journal of Immunology, 2012, 189, 4806-4815.	0.8	61
216	Low Interleukin-17A Production in Response to Fungal Pathogens in Patients with Chronic Granulomatous Disease. Journal of Interferon and Cytokine Research, 2012, 32, 159-168.	1,2	18

#	Article	IF	CITATIONS
217	IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3001-3005.	7.1	308
218	Primary immunodeficiencies of pattern recognition receptors. Journal of Internal Medicine, 2012, 272, 517-527.	6.0	14
219	Association of esophageal candidiasis and squamous cell carcinoma. Medical Mycology Case Reports, 2012, 1, 5-8.	1.3	45
220	Pattern recognition receptors and their role in invasive aspergillosis. Annals of the New York Academy of Sciences, 2012, 1273, 60-67.	3.8	31
221	Combination of biomarkers for the discrimination between bacterial and viral lower respiratory tract infections. Journal of Infection, 2012, 65, 490-495.	3.3	51
222	Murine Borrelia arthritis is highly dependent on ASC and caspase-1, but independent of NLRP3. Arthritis Research and Therapy, 2012, 14, R247.	3.5	20
223	Exposure to Candida albicans Polarizes a T-Cell Driven Arthritis Model towards Th17 Responses, Resulting in a More Destructive Arthritis. PLoS ONE, 2012, 7, e38889.	2.5	15
224	Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nature Reviews Microbiology, 2012, 10, 112-122.	28.6	693
225	Adjunctive immunotherapy with recombinant cytokines for the treatment of disseminated candidiasis. Clinical Microbiology and Infection, 2012, 18, 112-119.	6.0	29
226	Inflammasome is a central player in the induction of obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15324-15329.	7.1	602
227	Inhibition of caspase-1 activation in gram-negative sepsis and experimental endotoxemia. Critical Care, 2011, 15, R27.	5.8	61
228	Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut, 2011, 60, 1229-1235.	12.1	172
229	<i>STAT1</i> Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis. New England Journal of Medicine, 2011, 365, 54-61.	27.0	614
230	Defects of pattern recognition: primary immunodeficiencies of the innate immune system. Current Opinion in Pharmacology, 2011, 11, 412-422.	3.5	7
231	Inflammasome activation and IL- \hat{l}^2 and IL-18 processing during infection. Trends in Immunology, 2011, 32, 110-116.	6.8	577
232	Inflammasome-Independent Modulation of Cytokine Response by Autophagy in Human Cells. PLoS ONE, 2011, 6, e18666.	2.5	182
233	STAT1 Hyperphosphorylation and Defective IL12R/IL23R Signaling Underlie Defective Immunity in Autosomal Dominant Chronic Mucocutaneous Candidiasis. PLoS ONE, 2011, 6, e29248.	2.5	101
234	<i>Borrelia</i> species induce inflammasome activation and ILâ€17 production through a caspaseâ€1â€dependent mechanism. European Journal of Immunology, 2011, 41, 172-181.	2.9	37

#	Article	IF	CITATIONS
235	The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis. European Journal of Immunology, 2011, 41, 2260-2268.	2.9	126
236	The classical CD14 ⁺⁺ CD16 ^{â^'} monocytes, but not the patrolling CD14 ⁺ CD16 ⁺ monocytes, promote Th17 responses to <i>Candida albicans</i> European Journal of Immunology, 2011, 41, 2915-2924.	2.9	45
237	The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis and Rheumatism, 2011, 63, 1507-1516.	6.7	154
238	The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of <i>Candida albicans </i> Leukocyte Biology, 2011, 90, 357-366.	3.3	169
239	Role of Interleukin-23 (IL-23) Receptor Signaling for IL-17 Responses in Human Lyme Disease. Infection and Immunity, 2011, 79, 4681-4687.	2.2	34
240	DIFFERENTIAL EFFECTS OF IL-17 PATHWAY IN DISSEMINATED CANDIDIASIS AND ZYMOSAN-INDUCED MULTIPLE ORGAN FAILURE. Shock, 2010, 34, 407-411.	2.1	36
241	Pathogenesis of invasive candidiasis. Current Opinion in Critical Care, 2010, 16, 453-459.	3.2	75
242	T-cell Subsets and Antifungal Host Defenses. Current Fungal Infection Reports, 2010, 4, 238-243.	2.6	74
243	Engagement of fatty acids with tollâ \in like receptor 2 drives interleukinâ \in l $\hat{1}^2$ production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystalâ \in "induced gouty arthritis. Arthritis and Rheumatism, 2010, 62, 3237-3248.	6.7	259
244	Diversity: A Hallmark of Monocyte Society. Immunity, 2010, 33, 289-291.	14.3	35
245	Novel strategies for the prevention and treatment of <i>Candida < i>infections: the potential of immunotherapy. FEMS Microbiology Reviews, 2010, 34, 1063-1075.</i>	8.6	38
246	Differential susceptibility to lethal endotoxaemia in mice deficient in ILâ€1α, ILâ€1β or ILâ€1 receptor type I. Apmis, 2010, 118, 1000-1007.	2.0	24
247	Antiâ€ <i>Aspergillus</i> human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology, 2010, 130, 46-54.	4.4	115
248	Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clinical and Experimental Immunology, 2010, 159, 57-64.	2.6	31
249	IL-1 family nomenclature. Nature Immunology, 2010, 11, 973-973.	14.5	294
250	Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. Journal of Leukocyte Biology, 2010, 88, 227-232.	3.3	97
251	Inflammasome-independent Role of Apoptosis-associated Speck-like Protein Containing a CARD (ASC) in T Cell Priming Is Critical for Collagen-induced Arthritis. Journal of Biological Chemistry, 2010, 285, 12454-12462.	3.4	84
252	<i>Candida albicans</i> Dampens Host Defense by Downregulating IL-17 Production. Journal of Immunology, 2010, 185, 2450-2457.	0.8	78

#	Article	IF	CITATIONS
253	The Candida Th17 response is dependent on mannan- and Â-glucan-induced prostaglandin E2. International Immunology, 2010, 22, 889-895.	4.0	73
254	IL- $1\hat{l}^2$ Processing in Host Defense: Beyond the Inflammasomes. PLoS Pathogens, 2010, 6, e1000661.	4.7	427
255	Severe Candida spp. infections: new insights into natural immunity. International Journal of Antimicrobial Agents, 2010, 36, S58-S62.	2.5	57
256	Reactive oxygen species–independent activation of the IL-1β inflammasome in cells from patients with chronic granulomatous disease. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3030-3033.	7.1	226
257	Receptor Recognition of and Immune Intracellular Pathways for <i>Veillonella parvula</i> Lipopolysaccharide. Vaccine Journal, 2009, 16, 1804-1809.	3.1	50
258	Bypassing Pathogenâ€Induced Inflammasome Activation for the Regulation of Interleukinâ€1β Production by the Fungal Pathogen <i>Candida albicans</i> . Journal of Infectious Diseases, 2009, 199, 1087-1096.	4.0	70
259	Transcriptional and inflammasomeâ€mediated pathways for the induction of ILâ€1β production by <i>Mycobacterium tuberculosis</i> . European Journal of Immunology, 2009, 39, 1914-1922.	2.9	75
260	Legionella pneumophila DNA in serum samples during Legionnaires' disease in relation to C-reactive protein levels. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 371-376.	2.9	5
261	Caspase-1, but not ASC or NLRP3 inflammasome components, mediates IL-1beta activation and antifungal defense in disseminated candidiasis. Cytokine, 2009, 48, 120.	3.2	O
262	The Macrophage Mannose Receptor Induces IL-17 in Response to Candida albicans. Cell Host and Microbe, 2009, 5, 329-340.	11.0	294
263	Differential requirement for the activation of the inflammasome for processing and release of IL-1 \hat{l}^2 in monocytes and macrophages. Blood, 2009, 113, 2324-2335.	1.4	714
264	Th17 responses and host defense against microorganisms: an overview. BMB Reports, 2009, 42, 776-787.	2.4	91
265	Role of TLR1 and TLR6 in the host defense against disseminated candidiasis. FEMS Immunology and Medical Microbiology, 2008, 52, 118-123.	2.7	87
266	The role of NLRs and TLRs in the activation of the inflammasome. Expert Opinion on Biological Therapy, 2008, 8, 1867-1872.	3.1	57
267	Host–microbe interactions: innate pattern recognition of fungal pathogens. Current Opinion in Microbiology, 2008, 11, 305-312.	5.1	140
268	Prevalence, risk factors, and long-term outcomes of cerebral ischemia in hospitalized COVID-19 patients – study rationale and protocol of the CORONIS study: A multicentre prospective cohort study. European Stroke Journal, 0, , 239698732210925.	5 . 5	2
269	PTX3 Inhibits Complement-Driven Macrophage Activation to Restrain Granuloma Formation in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 0, , .	5.6	5